Monoamine Oxidase Inhibitors

All categories
DBCAT001004Therapeutic categoryC02KC

A chemically heterogeneous group of drugs that have in common the ability to block oxidative deamination of naturally occurring monoamines. (From Gilman, et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p414). A DrugBank category of 37 drugs. 24 of them are approved.

ATC classification
Part of
Antidepressive Agents
Also known as
Inhibitor, Monoamine Oxidase · Inhibitors, MAO · Inhibitors, Monoamine Oxidase · MAO i · MAO Inhibitors
Drugs

and 12 more with a free account

What you can answer from here — as of August 01, 2018

37DrugsEach linked to its full drug card
Sign in
56Drug targetsEvery drug–target pair in the class, with bond type
Sign in
1,410Marketed productsAcross the regions we cover, with dosage forms and routes
Sign in
18Routes of administrationHow the drugs in this class are given
Sign in
3SubcategoriesNarrower classes within this one
Sign in

Which targets do Monoamine Oxidase Inhibitors share, and which companies have late-stage candidates in this class?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In